Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00396981 · ClinicalTrials.gov registry record · Phase 4
MAPS Trial: Matrix And Platinum Science
A Phase 4 study, sponsored by Stryker Neurovascular.
- Completed
- Registry status
- Phase 4
- Development phase
- 626
- Enrollment target
NCT00396981: Completed Phase 4 study, sponsored by Stryker Neurovascular.
NCT00396981 is a Phase 4 study that has completed, run by Stryker Neurovascular. The registered enrollment target is 626 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (21% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00396981, a Phase 4 study, has completed, sponsored by Stryker Neurovascular.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 626 participants
- Enrollment target
Study Summary
Primary Objectives: * To establish Target Aneurysm Recurrence (TAR) rates for Matrix 2® and GDC® Coils used for the treatment of intracranial saccular aneurysms. TAR is defined as clinically relevant recurrence resulting in: target aneurysm reintervention, rupture/re-rupture and/or death from an unknown cause. * To correlate defined angiographic endpoints with TAR rates and assess their predictive value, thereby providing a framework to establish clinically relevant endpoints for future studies. Secondary Objectives: * To evaluate device characteristics, incidence and severity of device-related adverse events, including death, neurological deterioration and changes in functional abilities. * To establish angiographic recurrence rates for Matrix 2® and GDC® Coils used for the treatment of intracranial saccular aneurysms. * To explore an experimental, quantitative and volumetric endpoint and correlate these with existing qualitative assessments.
Interventions
- DEVICE Matrix 2® coils for endovascular aneurysm occlusion
- DEVICE GDC® coils for endovascular aneurysm occlusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 626 participants |
| Start Date | 2007-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
What the finished NCT00396981 record still lists
NCT00396981 is an interventional study that assigns participants to a tested intervention. The registered 626 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (21% higher).
The record links to 0 conditions, and to 2 interventions - of which Matrix 2® coils for endovascular aneurysm occlusion is the first listed.
NCT00396981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00396981 about?
NCT00396981 is a clinical study titled "MAPS Trial: Matrix And Platinum Science". Primary Objectives: * To establish Target Aneurysm Recurrence (TAR) rates for Matrix 2® and GDC® Coils used for the treatment of intracranial saccular aneurysms. TAR is defined as clinically relevant recurrence resulting in: target aneurysm reintervention, rupture/re-rupture and/or death from an un...
What is the current status of trial NCT00396981?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 626 participants. The study started on 2007-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT00396981?
The interventions under investigation include: Matrix 2® coils for endovascular aneurysm occlusion (DEVICE), GDC® coils for endovascular aneurysm occlusion (DEVICE).
Who is sponsoring clinical trial NCT00396981?
This trial is sponsored by Stryker Neurovascular, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00396981's enrollment target sits among peer trials
626 130th of 2000 higher than 1,871 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia